Reduced burden of disease and improved outcome of patients with rheumatoid factor positive rheumatoid arthritis compared with dropouts. A 10 year observational study

Journal of Rheumatology

Volumn 30, Issue SUPPL. 67, 2003, Pages 50-53

  Darmawan, John ^a   Rasker, Johannes J ^b   Nuralim, Hendri ^a  

^a Seroja Rheumatic Center   (Indonesia)

^b Seroja Rheumatic Center ^*

Author keywords

Burden of disease; Mortality; Outcome; Rheumatoid arthritis immunosuppressant; Rheumatoid factor positive

Indexed keywords

ANTIRHEUMATIC AGENT; C REACTIVE PROTEIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RHEUMATOID FACTOR;

ADULT; AGED; CLINICAL FEATURE; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME; ADOLESCENT; ARTICLE; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; CONVALESCENCE; DRUG COMBINATION; DRUG EFFECT; LONGITUDINAL STUDY; METABOLISM; MIDDLE AGED; PATIENT; PATIENT COMPLIANCE; PHYSIOLOGY; RECURRENT DISEASE; STATISTICS;

ADOLESCENT; ADULT; AGED; ARTHRITIS, RHEUMATOID; C-REACTIVE PROTEIN; DISEASE PROGRESSION; DRUG COMBINATIONS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PATIENT DROPOUTS; RECOVERY OF FUNCTION; RECURRENCE; RHEUMATOID FACTOR; TREATMENT OUTCOME;

EID: 1542494186     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (14)

1. Kremer JM. Safety, efficacy, and mortality in a longterm cohort of patients with rheumatoid arthritis taking methotrexate. Followup after a mean of 13.3 years. Arthritis Rheum 1997;40:984-5.
2. Pasero G, Priolo F, Marubini E, et al. Slow progression of joint damage in early rheumatoid arthritis treated with cyclosporine A. Arthritis Rheum 1996;39:1006-15.
3. Goldblum R. Therapy of rheumatoid arthritis with mycophenolate mofetil. Clin Exp Rheumatol 1993;11 Suppl 8:S117-9.
4. Tugwell P, Pincus T, Yocum D, et al. Combination therapy with cyclosporin and methotrexate in severe rheumatoid arthritis. N Engl J Med 1995;333:137-41.
5. Scott DG, Bacon PA. Intravenous cyclophosphamide plus methylprednisolone in treatment of systemic rheumatoid vasculitis. Am J Med 1984;76:377-84.
6. Calguneri M, Pay S, Caliskaner Z, et al. Combination therapy versus monotherapy for the treatment of patients with rheumatoid arthritis. Clin Exp Rheumatol 1999;17:699-704.
7. Rau R, Schleuser B, Herborn G, Karger T. Longterm treatment of destructive rheumatoid arthritis with methotrexate. J Rheumatol 1997;24:1881-9.
8. Devlin J, Gough A, Huissoon A, et al. The acute phase and function in early rheumatoid arthritis. C-reactive protein levels correlate with outcome. J Rheumatol 1997;24:9-13.
9. Plant MJ, Williams AL, O'Sullivan MM, Lewis PA, Coles EC, Dessop JD. Relationship between time-integrated C-reactive protein levels and radiologic progression in patients with rheumatoid arthritis. Arthritis Rheum 2000;43:1473-7.
10. van Leeuwen MA, van Rijswijk MH, Sluiter WJ, et al. Individual relationship between progression of radiological damage and the acute phase response in early rheumatoid arthritis. Towards development of a decision support system. J Rheumatol 1997;24:20-7.
11. Hammond A, Freeman K. One-year outcomes of a randomized controlled trial of an educational-behavioural joint protection programme for people with rheumatoid arthritis. Rheumatology 2001;40:1044-51.
12. Anderson JJ, Wells G, Verhoeven AC, Felson DT. Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. Arthritis Rheum 2000;43:22-9.
13. Haubitz M, Schellong S, Gobel U, et al. Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement: a prospective, randomized study. Arthritis Rheum 1998;41:1835-44.
14. Petri M, Zonana-Nacach A, Barr S, Magder L. Damage in systemic lupus erythematosus is dependent on dose and mode of delivery of corticosteroid [abstract]. Arthritis Rheum 1999;42 Suppl:S97.